It is commonly thought that high-insulin plasma levels in pre-diabetic to type 2 diabetes mellitus (T2DM) patients contributes to AD development, with increasing evidence suggesting an exacerbation of cognitive impairment, neuroinflammation, Aβ aggregation, and tau hyperphosphorylation in AD [70,71,72]. The gene discussed is MAPT; the disease is Alzheimer disease.